Bristol-Myers Squibb Co.

NYSE:BMY   3:59:59 PM EDT
64.68
+0.73 (+1.14%)
5:05:55 PM EDT: $64.81 +0.13 (+0.20%)
Products, Litigation

Cipla Ltd Says Settlement Of Revlimid (Lenalidomide) Capsules Patent Litigation

Published: 12/11/2020 14:36 GMT
Bristol-Myers Squibb Co. (BMY) - Cipla Ltd Says Announces Settlement of Revlimid® (lenalidomide) Capsules Patent Litigation.
Cipla Ltd - Celgene Agreed to Provide Co With License to Patents Needed to Make, Sell Some Volume-limited Amounts of Generic Lenalidomide in U.S.cipla - Ability to Market Lenalidomide in U.S. to Be Contingent on Obtaining Approval of Abbreviated New Drug Application.